Contribute Try STAT+ Today

WASHINGTON — President Trump used a glitzy Rose Garden address, flanked by pharmaceutical company CEOs and patient advocates, to boast of his administration’s successes lowering drug prices and to detract from his political rivals’ efforts on the same issue.

But the news he was touting was modest at best: Drug makers agreed to participate in a minor, voluntary Medicare program that will likely only provide a limited discount on insulin for a small subset of the 60 million seniors with Medicare coverage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Nice article Nicholas. One question. Is there any evidence that the drug manufacturers actualyl will get paid less or is this just a reduction in co-pays (with Medicare presumably picking up the difference)? The statements I have read seem very carefully worded to talk about reducing co-pays but this is the first article I have read that intimates that the manufacturers may actually get paid less.

  • So this proposal is a total PR con job ; the fact is that in year 2018 the US residents spent 365 BILLION on drugs that is 1 TRILLION in 3 years ; furthermore drugs costs at VA are 70% cheaper overall than Medicare drug prices; BIG PHARMA brought the votes in congress via K street to not allow Medicare the ability to negotiate any drug prices at all ; lastly Pelosi touted a few months ago in the press savings of 50 million per year for seniors on drugs compared to 365 Billion it is not even a comma in a paragraph ; all facts they do not want the American people to know about

  • Bankrupting people with medical bills is another avenue to consolidate wealth to the top. If these policies create another recession the rich can buy on the cheap and consolidate even more wealth, this process is repeated until we are left with serfs and lords. Until they come up with something am wearing a mask.

  • typical wash insider giving us all things bad about trump…
    i hope your tds meds price goes down…
    you are going to need more after nov….
    poor unjolly nicholas…

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy